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Mitochondria are key players in the regulation of
T cell biology by dynamically responding to cell
needs, but how these dynamics integrate in T cells
is still poorly understood. We show here that the
mitochondrial pro-fission protein Drp1 fostersmigra-
tion and expansion of developing thymocytes both
in vitro and in vivo. In addition, we find that Drp1 sus-
tains in vitro clonal expansion and cMyc-dependent
metabolic reprogramming upon activation, also
regulating effector T cell numbers in vivo. Migration
and extravasation defects are also exhibited in
Drp1-deficient mature T cells, unveiling its crucial
role in controlling both T cell recirculation in second-
ary lymphoid organs and accumulation at tumor
sites. Moreover, the observed Drp1-dependent
imbalance toward a memory-like phenotype favors
T cell exhaustion in the tumor microenvironment.
All of these findings support a crucial role for Drp1
in several processes during T cell development and
in anti-tumor immune-surveillance.
INTRODUCTION
Mitochondrial dynamics proteins orchestrate the morphology of
mitochondria in eukaryotic cells. The main protein implicated in
mitochondrial fragmentation is the GTPase dynamin-related pro-
tein-1 (Drp1) (Otera et al., 2013). This protein is recruited from the
cytosol upon different post-translational modifications (Chang
and Blackstone, 2010) and accumulates onmitochondria through
interaction with different receptors (Loso´n et al., 2013). Besides
regulating mitochondrial metabolism, mitophagy, and cyto-
chrome c release (Twig and Shirihai, 2011; Youle and Karbowski,Cell Repor
This is an open access article under the CC BY-N2005), Drp1 is also essential for cell division (Ishihara et al., 2009;
Qian et al., 2012; Zhan et al., 2016). In addition, Drp1 controls
in vitromigration of both metastatic cells (Ferreira-da-Silva et al.,
2015; Zhao et al., 2013) and lymphocytes (Campello et al., 2006).
Most of these processes, such as proliferation, apoptosis,
migration, and metabolic reprogramming, occur physiologically
in T cells. During their development, T cell precursors massively
proliferate and migrate extensively inside the thymus, undergo-
ing the processes of positive and negative selection (Klein
et al., 2014). When matured, these cells re-circulate in the pe-
ripheral blood and accumulate into secondary lymphoid organs
(SLOs) or in target tissues (Muller, 2014) by crossing the endo-
thelial blood barrier, a process heavily relying on myosin activity
(Jacobelli et al., 2013). T lymphocytes accumulating in a tumor
lesion are known as tumor-infiltrating lymphocytes (TILs). High
amounts of infiltrating cytotoxic CD8+ TILs have been associ-
ated with better survival in patients affected by different tumors
(Galon et al., 2006) and are emerging as a promising tool for
adoptive cell immunotherapy (ACI) (Fridman et al., 2011). Never-
theless, in the tumor microenvironment, TILs may also undergo
functional inactivation, acquiring a so-called exhausted pheno-
type (Wherry and Kurachi, 2015).
Interestingly, optimal T cell activation requires Drp1-depen-
dent mitochondrion accumulation at the immunological synapse
(IS) (Baixauli et al., 2011). In addition, although effector T (TE)
cells show a fragmented network and rely on aerobic glycolysis,
memory T (TM) cells show a more fused network and switch their
metabolism toward oxidative phosphorylation (OXPHOS) (Buck
et al., 2016).
Given the elucidated physiological roles of mitochondrial
fission, we investigated and unveiled a role of Drp1-dependent
mitochondrial fission in regulating T lymphocyte development,
homeostasis, and, consequently, immune-surveillance in vivo.
Our findings show that Drp1 is essential to produce a correct
number of thymocytes by affecting their development, to allow
efficient TE activation and expansion upon stimulation throughts 25, 3059–3073, December 11, 2018 ª 2018 The Author(s). 3059
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Drp1 Regulates the Number of Developing Thymocytes and Mature T Cells
(A) Total number of thymocytes isolated from +/+ cre+ control and fl/fl cre+ Drp1 conditional KO mice (n = 19).
(B) Representative pictures and size quantification of thymic lobes from +/+ cre+ and fl/fl cre+ mice (n = 6).
(C–E) Total numbers of thymocytes subsets (C and D) and relative percentage (E) according to CD4 and CD8 expression in +/+ cre+ control and fl/fl cre+ Drp1 KO
mice (DN, double negative; DP, double positive; SP4/8, single positive-4 and -8 (n = 7).
(F and G) Total number of CD4+ and CD8+ T cells (F), B cells, natural killer (NK) cells, macrophages (Mph), and other major histocompatibility complex class II (I-A
and I-E) (MHC-IA and -IE+)myeloid cells (G) isolated from the spleen (n = 9) and blood permilliliter (n = 4) in +/+ cre+ control and fl/fl cre+Drp1 conditional KOmice.
(H) Representative pictures and size quantification of spleens from +/+ cre+ and fl/fl cre+ mice (n = 6).
Data are reported as mean ± SEM. Significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.the mammalian target of rapamycin (mTOR)-cMyc axis, to exert
effective migration into both SLOs and tumor sites, and to regu-
late TIL exhaustion by controlling the effector or memory differ-
entiation balance. Moreover, we found that extracellular signal-
regulated kinase (ERK) mainly regulates Drp1 activation during
both T cell receptor (TCR) stimulation and migration. Therefore,
chronic inhibition of the main fission-promoting factor Drp1 in
T cell lineages determines deficiency of the immune system, re-
flecting impairment of immune-surveillance by these cells.
RESULTS
Drp1 Controls Developing Thymocyte and Mature T Cell
Homeostasis by Regulating Their Number without
Affecting Differentiation
Given the emerging role of Drp1 in orchestrating cell prolifera-
tion, migration, and death, crucial events during T cell thymic3060 Cell Reports 25, 3059–3073, December 11, 2018development, we hypothesized that this pro-fission protein had
the potential to affect the homeostasis of the developing immune
system. We therefore analyzed the effect of specific Drp1 abla-
tion during T cell development in Drp1fl/fl Lck:Cre conditional
knockout (Drp1 KO) mice (Ishihara et al., 2009). In 3-month-old
mice, we observed a strong reduction in total thymocyte number
(Figure 1A), paralleled by a reduction in the volume of the thymic
parenchyma (Figure 1B). Together with the absence of Drp1, we
confirmed the evidence of amore fusedmitochondrial network in
KO thymocytes (Figures S1A–S1C) without any significant alter-
ation of organelle functionality (Figures S1D–S1F). Notably,
although significantly reduced in number (Figures 1C and 1D),
themain subsets of thymocytes were correctly represented (Fig-
ure 1E), as well as the levels of TCRgd+ cells and thymic regula-
tory T cells (Tregs) and of the maturation markers CD69 and
CD62L (Figures S1G–S1I) and the viability of isolated subpopu-
lations (Figure S1J). In line with reduced thymocyte numbers,
Figure 2. Drp1 Is Involved in the Regulation of Thymocytes and Mature T Cell Proliferation
(A and B) Number of EdU+ +/+ cre+ control and fl/fl cre+ Drp1 KO thymocytes 3 and 4 days after in vitro activation (A, n = 5), also distinguishing DP and themean of
single positive 4 and single positive 8 (SP) thymocytes at 3 days (B, n = 6).
(C) Fold increase in the total number of viable (annexin V [annV]) CD8+ and CD4+ T cells 3, 4, and 6 days after in vitro activation (n = 5).
(D and E) Release from overnight (o.n.) nocodazole block for CFSE-labeled +/+ cre+ control and fl/fl cre+ Drp1 KO 5-day in vitro-activated CD8+ (D, n = 4) and
CD4+ (E, n = 4) T cells. The percentage of divided cells (halving of CFSEmean fluorescence index [MFI]) for each time point is shown in the corresponding graphs.
(legend continued on next page)
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we also found a specific 2-fold reduction in mature T cell
numbers in Drp1 KO mice, both in the blood and spleen (Fig-
ure 1F), left unrelieved in other leukocyte subpopulations (Fig-
ure 1G). The spleen, similar to the thymus, also showed a slightly
reduced volume (Figure 1H). All main mature T cell subtypes
(naive, effector, and memory) as well as other secondary popu-
lations were normally represented in the spleen or lymph nodes
(LNs) (Figures S1K–S1N). Moreover, the viability of splenic T cells
was unaltered (Figure S1O). Therefore, mature Drp1 KO T cells
also show a reduction in cell number while keeping the capability
to effectively differentiate into the main T cell subsets.
Altogether, these data indicate that the absence of Drp1 does
not compromise T cell differentiation; rather, it strongly restrains
the number of mature T cells that can patrol the organism against
external challenges.
Drp1 Modulates Proliferation of Thymocytes and
Activated Mature T Cells
Given such a reduction in cell number, we then investigated
whether Drp1 ablation could influence the clonal expansion of
thymocytes and of their naive T cell progeny. We observed
that both Drp1 KO thymocytes and mature T cells proliferated
less in vitro than control cells (Figures 2A–2C). This reduced
proliferation rate was not due to defective redistribution of mito-
chondria to daughter cells during mitosis (Figure S2A). In can-
cer cells, Drp1 ablation prolongs mitosis length because of hy-
perfused mitochondria, which engulf centrosomes and disrupt
their normal morphology (Qian et al., 2012). Interestingly, we
also found the same defects in Drp1 KO thymocytes and
mature T cells after stimulation (Figures S2B and S2C; Figures
2D–2G). We also ruled out the possibility of reduced viability
(Figure S2D) or of impaired S-phase engagement in mature
Drp1 KO T cells (Figures S2E and S2F) without altered levels
of reactive oxygen species (ROS) (Figure S2G) or of DNA dam-
age (Figure S2H). Last, we confirmed such a specific role for
Drp1 by rescuing KO T cell clonal expansion through active
Drp1-S616E overexpression (Figure 2H). Next, we checked
whether such a delay in Drp1 KO T cell clonal expansion could
also be observed in vivo after antigen recognition. To verify this
hypothesis, we pulsed control and conditional Drp1 KO mice
with lipopolysaccharide (LPS) and a protein extract of MC38
tumor cells. After 3 days, we found a reduced number of
H2Kb:KSPWFTTL dextramer-positive CD8+ cells (which specif-
ically recognize the immuno-dominant MC38 antigen; Chiodoni
et al., 1999) in the spleen of KO mice compared with controls
(Figure 2I). Similarly, the expansion of CD8+ T cells in the drain-
ing LN (DLN) of MC38-derived tumor-bearing (McIntyre et al.,(F) Representative confocal planes of the centrosome (g-tubulin) morphology and
fl/fl cre+ Drp1 KO T cells with aberrant centrosome morphology (n = 3).
(G) Relative position of centrosomes (the white arrow points to an altered centros
fixation) in T cells, irrespective of the genotype (n = 3).
(H) Fold increase in cell number upon in vitro IL-2-induced expansion in +/+ cre+
pEYFP-C1 or pEYFP-C1-Drp1-S616E plasmids (n = 3).
(I) Total number of dextramer+ CD8+ cells recovered from spleens of +/+ cre+
(unpulsed) or LPS and MC38 extract (pulsed) (n = 9 control [ctrl]; 8 KO).
(J) Total number of CD8+ T cells isolated from contralateral inguinal lymph nodes
KO mice bearing 14-day-old MC38-derived tumors (n = 6 ctrl, 4 KO).
Data are represented as mean ± SEM. Scale bar, 5 mm in (F) and (G). Significance
3062 Cell Reports 25, 3059–3073, December 11, 20182015) Drp1 KO mice, was strongly reduced compared with con-
trol mice (Figure 2J).
Altogether, these data suggest that Drp1 is crucial to sustain
the generation of an optimal number of both developing thymo-
cytes and activated T cells upon challenge.
Drp1 Is Required to Promote cMyc Activation upon TCR
Engagement
Alterations inmitochondrial dynamics can influence the effector or
memory differentiation after T cell activation by directly modu-
lating T cell metabolism, which, in turn, dictates T cell fate (Buck
et al., 2016). However, the molecular mechanism of this associa-
tion is not fully understood. Interestingly, Drp1 silencing in T cells
prevents mitochondrial accumulation at IS and excessively in-
creases calcium influx upon activation (Baixauli et al., 2011).
Consistent with this, although our Drp1 KO T cells correctly ex-
pressed several activation markers upon stimulation, they did
not accumulate mitochondria at IS and displayed a stronger cal-
cium influx (Figures S3A, 3A, and 3B). To investigate the
consequences of such dysregulation, we reasoned that stimula-
tion-dependent calcium increase promotes the activation of
AMP-activated protein kinase a (AMPKa) (Tama´s et al., 2006),
which, in turn, controls metabolic adaptation, by negatively regu-
lating mTOR (Blagih et al., 2015). mTOR is a master gene in pro-
moting the metabolic reprogramming of T cells upon activation
and also by positively acting on cMyc translation (West et al.,
1998). We therefore asked whether such an AMPK-mTOR-cMyc
axis may be altered in KO cells. We first confirmed the presence
of this regulatory pathway in our wild-type (WT) T cells (Figures
S3B–S3D). Then we looked at Drp1 KO T cells, in which calcium
influx is increased. As expected, we found increased levels of
active AMPKa, reduced levels of active mTOR, and lower expres-
sion of cMyc (Figure 3C). Last, we confirmed that the observed al-
terations in KOT cells originate from such a dysregulated pathway
because in KO T cells, increased AMPKa activation upon TCR
stimulation depends on calcium influx, as shown by using calcium
chelators (Figure 3D), and downregulation of mTOR signaling and
cMyc expression are due to AMPKa over-activation, as shown in
AMPKa inhibitor-driven rescue experiments (Figure 3E).
In sum, the altered calcium influx in the absence of Drp1 im-
pairs cMyc upregulation following T cell activation.
Drp1 Supports Metabolic Reprogramming of TE Cells
upon Activation
Because cMyc is required for the transcription of metabolic
genes in T cells upon activation (Wang et al., 2011), its reduced
expression in Drp1 KO T cells may affect the transcriptionquantification of the percentage of 6-day in vitro-activated +/+ cre+ control and
ome structure) and mitochondria (TOM20, low resolution because of methanol
control and fl/fl cre+ Drp1 KO T cells after electroporating either empty vector
control and fl/fl cre+ Drp1 KO mice 4 days after i.p. injection with LPS alone
(CLNs) and draining inguinal LNs (DLNs) of +/+ cre+ control and fl/fl cre+ Drp1
is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.
(legend on next page)
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profile of these cells. Indeed, we observed that KO cells show
reduced transcription of many cMyc-dependent metabolic
genes (Wang et al., 2011), particularly those related to the
glycolytic pathway (Figures 3F, 3G, S3E, and S3F; Table S1).
Consequently, glycolysis is downregulated at the transcriptional
level in Drp1 KO cells, at variance with OXPHOS, tricarboxylic
acid (TCA) cycle and fatty acid (FA) synthesis, and b-oxidation,
which are upregulated (Figures 3G, S3E, and S3F; Table S1).
This altered gene expression may predispose Drp1 KO T cells
to an altered metabolic status. Indeed, KO T cells showed a
reduction in their glycolytic rate (Figures 3H and S3G) and an in-
crease in their OXPHOS (Figures 3I and S3H), which can be at
least partially due to augmented levels of FA oxidation (Figures
3J and S3I). These alterations are not related to the amount of
mitochondrial mass and the membrane potential or to the levels
of glucose uptake or the amount of ATP produced because
these parameters are not affected in KO T cells (Figures S3J–
S3L). Although TE cells are mainly glycolytic, TM cells preferen-
tially rely on FA-dependent oxidative metabolism (O’Sullivan
et al., 2014). Interestingly, both inhibition of glycolysis (Sukumar
et al., 2013) and a forced increase in FA oxidation rate
(O’Sullivan et al., 2014) or OXPHOS (Buck et al., 2016) promote
a TE-to-TM shift after activation. Because the metabolism of
Drp1 KO T cells is completely re-shaped from a glycolytic
(TE-like) toward an oxidative (TM-like) one, we asked whether
our Drp1 KO T cells may also show a TM-like phenotype, even
when cultured under effector-promoting conditions. Indeed,
we observed such a TE-to-TM shift, as indicated by altered
CD127 and KLRG1 expression and the ratio between Tbet
and Eomes expression, with a higher production of inter-
leukin-2 (IL-2) (only for CD8+) and interferon g (IFNg) (Figures
3K and S3M). The latter is correctly released after stimulation
(Figure S3N), suggesting that the Drp1 absence does not
per se compromise cytokine release from T cells.Figure 3. Drp1 Controls the Metabolic Reprogramming of Activated T
(A) Mitochondria (TOM20) distribution in +/+ cre+ control and fl/fl cre+ Drp1 KO T c
CD3 antibody, red) (n = 4).
(B) Fluo3-AM-loaded +/+ cre+ control and fl/fl cre+ Drp1 KO T cells were incuba
a secondary antibody was added, and fluorescence was acquired up to 6 min
fluorescence relative to baseline is reported in the graph on the right (n = 5 ctrl, 4
(C) Expression levels of the indicated (phospho)-protein in +/+ cre+ control and fl/fl
the KO:ctrl ratio for the indicated (phospho)-proteins is reported in the graph on t
48 hr post-stimulation (maximal upregulation), but similar results were also obtai
(D and E) Expression levels and relative quantifications of the indicated (phospho)
5 hr in the presence of the calcium chelators 1,2-bis(o-aminophenoxy)ethane-N,N
the AMPK inhibitor Compound-C (E, n = 3).
(F and G) RNA sequencing (RNA-seq) analysis in 3-day in vitro-activated +/+ cre
(F) Heatmap of cMyc-dependent metabolic genes in T cells (cMyc-MG) expres
highlighted.
(G) The differential mRNA expressions (normalized association score) from enrich
additional metabolic pathways (whose heatmaps are reported in Figure S3F). TC
thesis; FAO, fatty acid oxidation. For each group, transcriptional enrichment in KO
no net difference in black (n = 3).
(H–J) Seahorse analysis of extracellular acidification rate (ECAR) (H) and oxygen co
and fl/fl cre+ Drp1 KO CD8+ T cells (2-DG, 2-deoxyglucose; Rot/an, rotenone an
etomoxir (J). The following parameters were quantified: glycolysis (Glyc), maxima
capacity (MRC), and basal (basal) and maximal (max) FA oxidation (n = 3).
(K) MFI for IL7Ra (n = 17), CD44 (n = 12), KLRG1 (n = 9), IFNg (n = 10), TNF-a (n = 6)
activated CD8+ +/+ cre+ control and fl/fl cre+ Drp1 KO T cells under the indicate
Data are represented as mean ± SEM. Scale bar, 10 mm in (A). Significance is in
3064 Cell Reports 25, 3059–3073, December 11, 2018Therefore, Drp1 KO T cells shifted toward a memory-like
phenotype upon in vitro activation because of their inability to
fragment their mitochondrial network and the consequent down-
regulation of cMyc activity.
Drp1 Avoids Thymocyte Cell Death in Thymic Cortical
Areas and Directs Their Cortico-medullary Migration
Given the existing data in vitro regarding the role of mitochondrial
dynamics in human lymphocytemigration (Campello et al., 2006),
we hypothesized that the impairment in Drp1 KO thymocyte
development could be partially ascribed to a migratory defect
of these cells. As expected, upon chemokine stimulation, WT
thymocyte mitochondria accumulate at the uropod around the
microtubule-organizing center (MTOC) in a microtubule-depen-
dent way and actively fragment prior to transport along microtu-
bules, in line with the observed activation of the pro-fission pro-
tein Drp1 by Ser616 phosphorylation (Figures 4A–4E). Such
mitochondrial fragmentation failed in Drp1 KO thymocytes,
which, as a consequence, showed defective cell polarization
upon chemokine stimulation (Figures 4D and 4F), thus indeed
recapitulating the same mechanism observed in other mature
cells (Campello et al., 2006; da Silva et al., 2014; Zhao et al.,
2013). Because accumulation of mitochondria at the uropod is
required for phosphorylation of myosin light chain 2 (MLC2)
(Campello et al., 2006), which sustains lymphocyte migration (Ja-
cobelli et al., 2013), we consistently found a lower uropodal
pMLC2 signal in WT cells treated with oligomycin (despite any
prevention ofmitochondrial relocalization) and in Drp1KO thymo-
cytes compared with WT ones (Figures S4A and S4B) and a
reduced in vitro migration rate in all main Drp1 KO thymocyte
subsets irrespective of the thymic chemokines used and despite
correct expression of the corresponding receptors (Figure 4G
and S4C). Interestingly, we observed a slight increase in the
percentage of single positive (SP) thymocytes expressingCells
ells stimulated with anti-CD3-coated beads (referred to as B, labeled with anti-
ted with the aCD3 antibody. After acquiring Fluo3-AM baseline fluorescence,
. The fold increase in maximum (at 2 min) and residual (at 5 min) Fluo3-AM
KO).
cre+ Drp1 KO T cells stimulated in vitro for the indicated time. Quantification of
he right (AMPK-mTOR, n = 5; cMyc, n = 4; S6, n = 3). cMyc levels are reported
ned at 5 hr.
-protein from +/+ cre+ control and fl/fl cre+ Drp1 KO T cells activated in vitro for
,N0,N0-tetraacetic acid acetoxymethyl ester (BAPTA-AM) and EDTA (D, n = 3) or
+ control and fl/fl cre+ Drp1 KO T cells.
sion in +/+ cre+ control and fl/fl cre+ Drp1 KO T cells, with glycolytic genes
ment gene set association analysis (GSAA) of the cMyc-MG group from (F) and
A, tricarboxylic acid; PPP, pentose phosphate pathway; FAS, fatty acid syn-
cells compared with controls is highlighted in red, downregulation in blue and
nsumption rate (OCR) (I and J) rates in 6-day in vitro-activated +/+ cre+ control
d antimycin). FA oxidation was measured with BSA-palmitate with or without
l glycolytic capacity (MGC); basal OXPHOS (basal OX), maximum respiratory
, IL-2 (n = 4), and IL-4 (n = 7) and for the Tbet:Eomes ratio (n = 8) in 6-day in vitro-
d polarizing conditions.
dicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3.
Figure 4. Drp1 Is Necessary to Sustain Thymocyte Migration, Controlling Their Distribution and Survival in Thymic Areas
(A–C) Mitochondria (TOM20) with the uropod marker ICAM1 (A, n = 3) or tubulin (B, n = 3) in WT thymocytes stimulated with CXCL12 or with tubulin in WT
thymocytes pre-treated with nocodazole (C, n = 3).
(D) Mitochondrial morphology (TOM20) in +/+ cre+ control and fl/fl cre+ Drp1 KO thymocytes treated with nocodazole and then stimulated with CXCL12. The
fusion index (STAR Methods) is reported in the graph (n = 2).
(E) Expression levels of the indicated (phospho)-proteins in +/+ cre+ control and fl/fl cre+ Drp1 KO thymocytes stimulated with CXCL12 or CCL21 chemokines
(n = 3).
(F) Mitochondria (TOM20) and the uropod marker ICAM1 in +/+ cre+ control and fl/fl cre+ Drp1 KO thymocytes stimulated with CXCL12. The percentage of cells
with colocalized mitochondria and ICAM1 is reported in the graph (n = 3).
(legend continued on next page)
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Sphingosine-1 phosphate receptor 1 (S1p-R1) (Figure S4D). This
could be a consequence of a defective thymocyte migration rate
in response to the S1p gradient, which is normally required for
thymus exit toward blood circulation of ‘‘freshly matured’’ thymo-
cyte (Matloubian et al., 2004). Indeed, an in vitro S1p gradient-
mediated migration assay on SP thymocytes confirmed our hy-
pothesis (Figure S4E). Because chemokine-driven cell migration
is essential for cortical area crawling and recruitment of maturing
thymocytes to medullary islets (Nitta et al., 2009; Plotkin et al.,
2003), the reduced in vitromigration rate of Drp1 KO thymocytes
could suggest an in vivo altered distribution of these cells in
different thymic areas. Indeed, we found a reduced proportion
of medullary thymocytes compared with cortical ones in KO
mice (Figure 4H). Such disproportion could be indicative of a
thymocyte inability to reach these areas and of a longer persis-
tence in the thymic cortex. We also found a slight reduction in
medullary islet (keratin-5+) mean area in Drp1 KO mice (Fig-
ure S4F), a phenotype normally associated with reduced
amounts of medullary thymocytes (Nitta et al., 2009). Thymocyte
migration is also essential for correct progression along the pos-
itive and negative selection processes; therefore, as an outcome
of their (in)efficiency, we looked at apoptosis in situ. Increased
apoptotic cell density limited to cortical areas of KO thymi (Fig-
ure 4I) was found, not as a result of different sensitivity to
apoptotic stimuli, as assessed in vitro (Figure S4G). However,
these alterations did not lead to the development of auto-reactive
T cells, as assessed by the absence of salivary gland infiltration
(Figure S4H), a common target of negative selection-dependent
auto-immunity (Nitta et al., 2009).
Taken together, these data indicate that Drp1 is required to
sustain the proper migration and survival of thymocytes in the
thymic parenchyma, thus being crucial for the correct develop-
ment of a normal T cell repertoire.
Drp1 RegulatesMature T Cell Extravasation and Homing
to Secondary Lymphoid Organs through Its ERK1/2-
Dependent Activation
We next investigated whether the defect in cell migration was
maintained in mature Drp1 KO T cells following in vitro activation
and whether this could lead to an impairment in extravasation
toward SLOs and inflamed or endangered sites (Muller, 2014).
As expected, in vitro-activated Drp1 KO mature T cells recapitu-
lated the same results obtained in thymocytes in terms of impair-
ment in mitochondria and cell polarization and MLC2 phos-
phorylation (Figures 5A and S5A). Notably, myosin activity,
depending on ATP-fueled phosphorylation of its MLC2 subunit
(Tan et al., 1992), is even more critical in T cell extravasation
(Jacobelli et al., 2013); Drp1 KO lymphocytes were indeed defec-
tive upon crossing a tumor necrosis factor a (TNF-a)-activated(G) Transwell migration assay of +/+ cre+ control and fl/fl cre+ Drp1 KO thymocy
(H) Representative images and relative quantification of cells’ MFI of CD4+ and
from +/+ cre+ control and fl/fl cre+ Drp1 KO thymic sections (n = 8). Shown on t
(I) Representative terminal deoxynucleotidyl transferase dUTP nick end labeling
differentiated medulla (K5+) or cortical areas. Shown below is a relative quantifica
automatically identified by Volocity software, indicated as yellow spots in the ‘‘co
Data are represented as mean ± SEM. Scale bars, 5 mm in (A)–(D) and (F), 50 mm in
***p < 0.001. See also Figure S4.
3066 Cell Reports 25, 3059–3073, December 11, 2018endothelial cell monolayer. Despite normal adhesion, diapedesis
was severely impaired in KOcells, and their crawlingwas severely
altered (Figure 5B; VideoS1). The transmigration defect was inde-
pendent of the chemokine used and of defective expression of
adhesion molecules or chemokine receptors (Figures S5B and
S5C). Prompted by our in vitro results, we next investigated the
extravasation in vivo. Indeed, in vitro-activated andCarboxyfluor-
escein succinimidyl ester (CFSE)-labeledDrp1KOT cells showed
defective accumulation inside SLOs compared with eFluor670-
labeled WT control cells 24 hr after intravenous (i.v.) injection
into recipient WT mice (Figure 5C). By contrast, when inside the
LNs, Drp1 KO T cells were evenly distributed among B and
T cell zones (Figure S5D). Also, we confirmed the context-specific
role of Drp1 by rescuing KO T cell migration upon active
Drp1-S616E overexpression (Figure S5E).
Last, we found that, similarly to thymocytes, Drp1 is actively
phosphorylated on Ser616 upon chemokine stimulation inmature
T cells, further linking chemokine receptor stimulation with mito-
chondrial fission (Figure 5D). Interestingly, the mitogen-activated
protein kinase (MAPK)-ERK pathway is activated downstream of
chemokine receptor signaling (Bonacchi et al., 2001), and ERK is
a known regulator of Drp1 phosphorylation on Ser616 (Kashatus
et al., 2015). Consistently, the ERK inhibitor FR180204 prevented
Drp1 phosphorylation and mitochondrial fragmentation in lym-
phocytes upon chemokine stimulation and in TE cells upon TCR
engagement (Figures 5D–5F), and another signal, the latter, trig-
gering both MAPK-ERK activation (Lapinski and King, 2012) and
mitochondrial fission (Buck et al., 2016). Of note, we observed
that mitochondrial fragmentation is impaired in Drp1 KO cells
upon TCR engagement, confirming its direct dependence on
Drp1 activity under these conditions (Figures S5F and S5G).
Altogether, these results indicate a reduced ability of Drp1-
deficient T cells to recirculate in vivo inside SLOs, a pivotal pro-
cess for immune-surveillance.
Drp1 Ablation Favors Accelerated Tumor Growth by
Locally Reducing Infiltration and Increasing an
Exhausted Phenotype of T Cells
Given the reduced extravasation rate of Drp1 KO T cells in vivo,
we hypothesized that Drp1 ablation in the T cell lineage could
also affect local infiltration of these cells in a solid tumor site. To
explore this hypothesis, we chose a highly immunogenic solid tu-
mor model. We injected in vitro-activated and differently labeled
control and KO T cells in WT recipient mice bearing MC38-
derived tumors (McIntyre et al., 2015). We observed a reduced
ability of exogenous KO T cells to accumulate in the inguinal
DLN and isolated fewer KO TILs from the dissected tumor
mass (Figure 6A). This finding was also confirmed by immunoflu-
orescence on tumor slices (Figure S6A) and was even moretes in the presence of the indicated chemokines (n = 4).
CD8+ staining distribution in medulla (Keratin5+) and cortex (Keratin5) areas
he right are magnifications of the yellow squares on the left.
(TUNEL) assay in +/+ cre+ control and fl/fl cre+ Drp1 KO thymic sections with
tion of the Drp1 KO:control ratio of TUNEL+ cell density (cell number per area,
unt’’ panel) for cortical (K5) and medullary (K5+) areas (n = 5).
(H), and 200 mm in (I). Significance is indicated as follows: *p < 0.05, **p < 0.01,
Figure 5. Drp1 Is Essential to Promote Mature T Cell Extravasation and Homing into Secondary Lymphoid Organs and Is Regulated by ERK-
Mediated Phosphorylation
(A)Mitochondria (TOM20) and the uropodal marker (ICAM1) in +/+ cre+ control and fl/fl cre+ Drp1 KO6-day in vitro-activated T cells stimulated with CCL21 (n = 6).
(B) Activated eFluor 670-control (red) and CFSE-Drp1 KO (green) T cell extravasation across an endothelial monolayer. Shown are representative images and
quantifications of the Drp1 KO:control cell ratio for adhesion or extravasation by distinguishing the cells above (no arrows) or below (control, black arrows; KO,
white arrow) the endothelial monolayer (top, n = 4). Also shown is a representative image and quantifications of the mean speed and displacement rate for tracks
of control and Drp1 KO T cells migrating on and through the endothelial monolayer (bottom, n = 3). See also Video S1.
(C) I.v. injection of 1:1 in vitro-activated +/+ cre+ control (eFluor 670-labeled) and fl/fl cre+ Drp1 KO (CFSE-labeled) T cells into a WT recipient. After 24 hr, the
KO:control ratio between cells recovered from the blood, spleen, and LN pool was quantified (n = 9).
(legend continued on next page)
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striking when limiting the analysis to CD8+ cells, the cell popula-
tion preferentially recruited into tumormasses compared with the
CD4+ one (Figure 6B). Therefore, these data suggest that Drp1
KO T cells, besides recirculating less inside SLOs, also have an
impaired ability to reach a tumor mass from the blood circulation.
Based on such in vivo evidence, we next asked whether the
adaptive immune-surveillance against tumors could be compro-
mised inmicewith a specific Drp1 deficiency in the T cell lineage.
To this end, we subcutaneously (s.c.) injected MC38 tumor cells
into WT and Drp1 conditional KO mice and monitored the tumor
mass growth for up to 18 days. Interestingly, tumors grew faster
in Drp1 KOmice (Figure 6C; Figure S6B) and, after surgical exci-
sion, had a significantly higher volume and weight compared
with time-matched tumors grown in WT mice (Figures 6C and
6D). As expected, we found fewer CD8+ and CD4+ T cells in
the inguinal DLNs (Figure 6E) and the tumor masses of KO
mice (Figure 6F), whereas this was not observed in other leuko-
cyte populations (Figure S6C). Moreover, we found a normal ra-
tio between CD4+ effector and regulatory T cells (Figure S6D).
The density reduction of lymphocytes infiltrating tumor foci
was also confirmed in situ by immunohistochemistry (IHC) (Fig-
ure 6G) and also observedwhen considering only the dextramer+
Drp1 KO CD8+ TILs (Figure 6H), which specifically recognize the
main tumor immuno-antigen for the correct elimination of tumor
cells. Indeed, supporting the idea of T lymphocyte-mediated
control of the tumor growth in this model, we found that the
tumor mass strongly and inversely correlated with CD8+ TIL fre-
quency among all leukocytes (Figure 6I).
Of note, the faster tumor growth in Drp1 KO mice did not
depend on defective KO T cell cytotoxicity. Indeed, KO CD8+
splenocytes of MC38 tumor-bearing mice correctly degranu-
lated and released granzymeB in vitro upon stimulation or in
the presence of MC38 target cells, which were efficiently killed
by WT and KO T cells at the same rate (Figures S6E–S6H).
Interestingly, in line with our in vitro data indicating a TE-to-TM
shift after Drp1KOT cell activation, we found, in vivo, a significantly
increased proportion of CX3CR1neg memory precursor effector
cells (MPECs) over CX3CR1high short-living effector cells (SLECs)
(Gerlach et al., 2016) among KO CD8+ TILs (Figure 6J). This,
when combined with the overall reduction in KO CD8+ TILs in
the tumor mass, leads to a specific reduction in the total number
of SLECs (Figure S6I). Interestingly, memory T cells may
also spontaneously arise in vivo from naive T cells because of lym-
phopenia-induced proliferation (Cho et al., 2000; Goldrath et al.,
2000). However, WT and Drp1 KO naive T cells do not convert
into memory ones, regardless of the genetic background of recip-
ientmice (FigureS6J), excluding that the partial reduction inmature
T cell number observed in Drp1 KO mice may be a driver of such
increased generation of a memory-like phenotype in vivo, further
strengthening the role of the alteredmetabolism in such regulation.(D) Expression levels of the indicated (phospho)-protein in +/+ cre+ control and fl/fl
absence of the ERK inhibitor FR180204 (ERKi). Quantification of the fold increas
CCL21 stimulation is reported in the graph (n = 4).
(E and F)Mitochondrial network (E, TOM20, in green) andwestern blot (WB) analys
(0 hr) or activated in vitro for 48 hr in the presence or absence of FR180204 (ERK
Data are represented asmean ± SEM. Scale bars, 10 mm in (A) and (E) and 30 mm in
also Figure S5.
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hausted phenotype (TEX) than SLECs (Angelosanto et al., 2012),
we investigated whether their increased proportion in Drp1 KO
TILs could correlate with a TEX increase. Indeed, we found an
increase in PD-1+ (marker of TEX) cells among KO CD8+ TILs
and, consistent with such increased MPECs and TEX genera-
tion, lower production of IFNg, lower expression of Tbet, and
higher expression of Eomes (Figures 6K and 6L). Notably,
Drp1 ablation does not affect, per se, PD-1 expression in
SLOs of tumor-free or tumor-bearing mice (Figures S6K and
6K) or in any of the three CX3CR1 subsets (negatively, interme-
diately, and highly expressed) of TILs from MC38-derived
tumors (Figure S6L). By contrast, we observed in vitro that
PD-1 upregulation upon repetitive cell stimulation cycles corre-
lates with increased levels of memory cells in Drp1 KO mice
during expansion phases (Figure S6M), further supporting the
existing correlation between Drp1 ablation, a MPEC pheno-
type, and the tendency to undergo functional exhaustion. This
evidence suggests that the increased amount of TEX cells
in Drp1 KO TILs is most likely a local consequence of the
SLEC-to-MPEC shift in the absence of Drp1.
Last, Drp1 KO T cells were also less able than WT cells to con-
trol tumor growth when injected i.v. into tumor-bearing WT mice
and poorly infiltrated the tumor mass (Figures 7A–7C), suggest-
ing the importance of preserving Drp1 activity in T cells for im-
muno-therapeutic applications in human cancer patients.
Overall, we can conclude that the faster tumor growth
observed in Drp1 KO mice correlates with a strong reduction in
TIL infiltration and effector functions. The former is due to
impaired (trans)migration and the latter due to a SLEC-to-
MPEC phenotype shift with the consequent generation of more
exhausted TILs.
DISCUSSION
Our data demonstrate that tumors have accelerated growth in
a mouse model in which mitochondrial fission is impaired by
specific deletion, early in development, of Drp1 in T lympho-
cytes. This is mainly due to reduced T cell infiltrates in the tumor
mass and increased levels of exhaustion, highlighting a crucial
impairment of lymphocyte immune-surveillance.
Interestingly, these defects involve T cell development as a
whole because proliferative and migratory defects are observed
starting from developing thymocytes. The reduction in thymo-
cyte cell number is partly due to a reduced proliferation rate
and partly due to increased apoptosis in cortical areas of the
thymus, where positive selection occurs (Klein et al., 2014). Inter-
estingly, Drp1-mediated thymocyte migration seems to be
required for their correct interaction with cortical, but not medul-
lary, antigen-presenting cells (APCs), locally promoting theircre+ Drp1 KO T cells stimulated with the CCL21 chemokine in the presence or
e in the expression level of the indicated phospho-proteins over control upon
is (F) of the levels of the indicated (phospho)-proteins inWT T cells unstimulated
i) (n = 3).
(B). Significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. See
Figure 6. Drp1 Is Required for T Cell Accumulation into Draining LNs and for Infiltration and Exhaustion into Tumor Masses during Immune-
Surveillance
(A and B) In vitro-activated control (eFluor670-labeled) and Drp1 KO (CFSE-labeled) T cells were injected i.v. into WT recipient mice bearing 13 day-old MC38-
derived tumors. After 24 hr, peripheral blood (PB), inguinal DLNs, and tumor masses (TILs) were collected, and the KO:control ratio (A, both total T cells or CD8+
T cells only) and the exogenous CD8+:CD4+ T cell ratio (B) (considering both control and KO cells) were quantified by flow cytometry (TILs, n = 4; DLNs, n = 6).
(C) Size of MC38-induced s.c. tumors in +/+ cre+ control and fl/fl cre+ Drp1 conditional KO mice at the indicated times (n = 11 ctrl, 8 KO).
(legend continued on next page)
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Figure 7. Reduced Protection in the Absence of Drp1 during Adop-
tive Cell Immunotherapy
(A) Experimental plan.
(B) Tumor size assessed in WT mice bearing MC38-derived tumors and
receiving mitochondria-tagged yellow fluorescent protein (mtYFP+) control
(+/+ cre+) or Drp1 KO (fl/fl cre+) T cell i.v. injection (n = 5 mice per group).
(C) Number of exogenous mtYFP+ control (+/+ cre+) or Drp1 KO (fl/fl cre+)
T cells injected into tumor-bearing WT mice and recovered from the tumor
mass after isolation (n = 4 ctrl, 3 KO).
Data are represented as mean ± SEM. Significance is indicated as follows:
*p < 0.05, **p < 0.01.survival. Of note, because medullary thymocytes move more
rapidly and straighter than cortical ones (Ehrlich et al., 2009),
defective mitochondrial relocation to the uropod could more
severely affect thymocytes’ capability to efficiently change tra-
jectory over time rather than their absolute migration rate.
In mature T cells, our data indicate that Drp1 regulates three
distinct cellular processes, all dependent on mitochondrial
dynamics and all contributing to immune-surveillance against(D) Tumor weight graphs and pictures of representative MC38-derived tumors is
(E and F) Absolute number of +/+ cre+ control and fl/fl cre+ Drp1 KOCD4+ and CD
(F) 18 days after s.c. tumor cell injection (n = 14 ctrl, 11 KO).
(G) CD8+ or CD4+ IHC staining on 18-day-grown isolated MC38-derived tumor
sponding graph (n = 5 ctrl, 6 KO).
(H) Density of dextramer+ CD8+ TILs per field, calculated by combining the perce
quantification of total CD8+ TIL density by IHC (n = 5 ctrl, 5 KO).
(I) Correlation between tumor size and CD8+ TIL percentage among CD45+ cell
p = 0.019 (n = 5 ctrl, 7 KO).
(J and K) Relative expression of CX3CR1 (negatively, intermediately, or highly ex
CD8+CD44+ T cells collected from DLNs or from MC38-derived tumors (TILs) 18
(L) Percentage of CD44+ cells among all CD8+ and of IFNg+, Tbet+, and Eomes+
of +/+ cre+ control and fl/fl cre+ Drp1 KO mice 18 days after s.c. tumor cell injec
Data are represented as mean ± SEM in (C), (E), and (J) and as dot density plot
independent experiments. Scale bars, 5 mm in (D) and 100 mm in (G). Significance
3070 Cell Reports 25, 3059–3073, December 11, 2018tumor growth: metabolic reprogramming, proliferation, and
migration.
It has been reported that, during TE cell differentiation, mito-
chondrial fragmentation favors disassembly of electron trans-
port chain (ETC) complexes, reducing the OXPHOS rate while fa-
voring glycolysis (Buck et al., 2016). Besides recapitulating these
metabolic data under our conditions, we observed that such
fragmentation is dependent on ERK-mediated Drp1 activation.
Of the highest importance is that our data indicate that Drp1
may also sustain glycolysis in TE cells, with an additional, but
not mutually exclusive, transcriptional mechanism still depen-
dent on mitochondrial shaping. Indeed, in T cells lacking Drp1,
upon TCR engagement, we found increased extracellular cal-
cium uptake, most likely because of impaired relocation of
non-fragmented mitochondria at the IS (Baixauli et al., 2011).
This has as a consequence dramatic alteration of the AMPK-
mTOR-cMyc axis and reduced cMyc expression. Because
cMyc promotes the transcription of glycolytic enzymes in
T cells upon activation (Wang et al., 2011), it is not surprising
to observe that Drp1 KO T cells show defective transcription
of such enzymes and, as a consequence, a more oxidative
metabolism compared with WT cells. This, in turn, generates
a persistent mitochondrial morphology-dependent oxidative
metabolism that drives the generation of a memory-like pheno-
type, as suggested by Sukumar et al. (2013). Whether this mech-
anism may also explain the connection between mitochondrial
fission or fusion and glycolysis or OXPHOS in cancer cells will
be an important aspect to investigate in the future (Simula
et al., 2017). In addition, the OXPHOS-based metabolism of
Drp1 KO T cells also affects the generation of memory-like
T cells in vivo without any significant contribution of lymphope-
nia-induced proliferation in the conversion of naive T cells into
memory ones.
Our data also indicate that Drp1 is required to sustain optimal
T cell proliferation. However, this is not associated with the
altered metabolism of Drp1 KO T cells, as also demonstrated
for Drp1-silenced cancer cells (Qian et al., 2012). Indeed, nucle-
oside synthesis enzymes (data not shown), lipid metabolism,
ATP or ROS levels, and DNA damage are unaltered in Drp1 defi-
ciency. Consistent with this, KO T cells do not show any alter-
ation in their progression into S phase, as suggested by a similar
rate of 5-ethynyl-2’-deoxyuridine (EdU) incorporation. So how to
explain the effect of Drp1 on the rate of cell proliferation?olated 18 days after cell injection (n = 11 ctrl, 8 KO).
8+ T cells collected from inguinal DLNs (E) or fromMC38-derived tumors (TILs)
slices. Quantification of CD8+ and CD4+ TILs density is reported in the corre-
ntage of recovered CD8+ dextramer+ cells by cytofluorimetric analysis with the
s in tumor-bearing +/+ cre+ control and fl/fl cre+ Drp1 KO mice. R = 0.661,
pressed) (J, n = 9) or PD1 (K, n = 9) in +/+ cre+ control and fl/fl cre+ Drp1 KO
days after s.c. tumor cell injection.
cells among all CD8+CD44+ T cells isolated from DLNs or in the tumors (TILs)
tion and after 6 hr of in vitro T cell re-stimulation (n = 5 ctrl, 7 KO).
s in (A), (B), (D), (F)–(H), (K), and (L). Data are from two representative of four
is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S6.
Interestingly, in cancer cells (Qian et al., 2012), Drp1 ablation pro-
longsmitosis length because of hyperfused mitochondria, which
do not redistribute in the cytoplasm, as physiologically occurs
during mitosis, but accumulate and engulf the centrosomes
and disrupt their normal morphology, a phenotype clearly reca-
pitulated in our T cells.
Last, we found that Drp1 is required in mature T cells for their
correct migration. Although we already showed most of the
mechanistic details regarding the regulation of T cell migration
by mitochondrial dynamics (Campello et al., 2006), our study
directly identifies Drp1 as a key mediator of this process. Inter-
estingly, we also observed that Drp1 is actively phosphorylated
by ERK upon chemokine stimulation, similar to what was
observed upon T cell activation. This suggests that, besides can-
cer cells (Kashatus et al., 2015), the MAPK-ERK pathway is also
a key general regulator of mitochondrial dynamics in T cells in
different contexts. Because PD1+ exhausted T cells in chronic
viral infection show reduced motility and associated reduced
ERK activity (Zinselmeyer et al., 2013), it will be interesting in
the future to investigate whether enhancing Drp1 functionality
may restore TEX motility downstream of PD-1 and ERK de-regu-
lation. Further, the phosphorylation-driven impairment in myosin
activation we observed in KO T cells has been previously asso-
ciated with the requirement of mitochondrion-derived ATP
locally produced at the uropod (Campello et al., 2006). Interest-
ingly, defective migration is observed in KO T cells even though
they show a shift toward an OXPHOS-based metabolism, which
should, in principle, drive a highermigration rate, given the higher
competence to produce mitochondrion-derived ATP. This
apparent paradox further highlights the importance of a fine-tun-
ing modulation of mitochondria distribution to drive localized
production of mitochondria-derived ATP rather than that of the
general mitochondria functionality. Moreover, in the absence of
Drp1, cells are even unable to transmigrate. Drp1-deficient
T cells lacking mitochondria at the uropod do not promote
correct activation of themotormyosin, crucial for diapedesis (Ja-
cobelli et al., 2013), affecting the capacity of these cells to join
secondary lymphoid organs and to infiltrate any specific in-
flamed target site, such as a tumor lesion. It is thus not surprising
that the phenotype we observe in our model closely resembles
that observed in myosin-deficient mice (Jacobelli et al., 2013).
Also, the transmigration defects are nicely highlighted in the tu-
mor IHC pictures, where Drp1-deficient T cells are fewer, and
the few present ones are intriguingly retained in the capillaries
or in their strict proximity.
Taken together, our data can comprehensively explain our
main observation that mice lacking Drp1 in T cells were not
able to mount a correct immune response to tumor development
under conditions requiring very rapid and optimal SLEC infiltra-
tion (Ebert et al., 2016). Moreover, such a TM-like shift driven
by Drp1 deficiency was also associated in vivo with increased
levels of exhausted T cells, which preferentially originate from
memory rather than TE cells (Angelosanto et al., 2012), further
impairing immune-surveillance in a tumor mouse model where
an optimal TE cell response is required (Ebert et al., 2016).
In conclusion, our findings show that the absence of a
single protein, Drp1, in the T cell lineage determines defective
proliferation and migration during T cell thymic development.Consequently,micehavea reducednumber ofmature circulating
T cells that inherited the proliferative and migratory defects from
their progenitors and show defective production of TE progeny,
too. Thus, these cells recirculate less in secondary lymphoid
organs, proliferate less, and, eventually, do not reach target tis-
sues, where they would exploit their full defensive functions.
We can thus assign to Drp1 a crucial role in correct T cell
development and in the essential regulation of lymphocyte
immune-surveillance.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Models
C57BL/6 Lck:Cre transgenic mice purchased from Jackson Laboratory were crossed with C57BL/6 Drp1 floxed mice (Ishihara et al.,
2009), kind gift from Prof. Luca Scorrano (Venetian Institute of Molecular Medicine), to generate KO Drp1 fl/fl Lck:Cre mice (indicated
as fl/fl cre+ in the Fig.s) and control Drp1 +/+ Lck:Cre mice (+/+ cre+). ROSA26:mtYFP fl/fl mice (Sterky et al., 2011) have been
crossed to Drp1 floxed and Lck:cre mice to obtain mice with mtYFP-expressing T cells. All mice were bred and maintained under
conventional conditions at Plaisant (Castel Romano) and IRCCS Fondazione Santa Lucia Animal Facilities. They were kept in cages
of no more than 5-6 mice each, divided by sex, under 12h/12h light/dark cycle, with standard temperature, humidity and pressure
conditions according to FELASA guidelines. Small red squaredmice house and paper were used for cage enrichment. Frombreeding
until weaning a specific food (richer in fat and protein than the standard one used formaintenance) were used in all cages.Mice health
were monitored daily by veterinary staff and health analysis for pathogens were performed every three months according to FELASA
guidelines. Weaning was performed not earlier than 28 post-natal days. For all the experiments, mice were sacrificed by neck dislo-
cation at 2-3 months of age. Male mice have been used for tumor experiments, while all other analyses were performed indepen-
dently of sex. Blood has been collected from heart ventricles by syringe needle or from submandibular plexus. For thymus area mea-
surements, the following formula has been used: major axis*minor axis*pi-greek (approximated elliptical surface). Spleen area has
been quantified as a rectangular surface: major axis*minor axis. The mice protocols have been approved by the IRCCS Fondazione
Santa Lucia and the Plaisant Ethical Committees as well as by the Italian Ministry of Health (Authorization # 459/2015-PR). They have
been written following both the ARRIVE Guidelines, and the numeric details have been chosen following the criteria described in The
National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (https://www.nc3rs.org.uk/).
Primary Cells
Murine thymocytes and murine T cells have been cultivated in RPMI 1640 medium (GIBCO) supplemented with 10% Fetal Bovine
Serum (GIBCO), 2mM L-glutamine, 100U/ml penicillin/streptomycin, 1x GIBCO MEM Non-essential amino-acids, 1mM Sodium
piruvate, 100mg/ml Gentamycin and 55mM beta-mercaptoethanol (Thermo Fisher).
Cell lines
MC38 tumor cells have been cultured in complete DMEM medium (GIBCO) supplemented with 10% Fetal Bovine Serum (GIBCO),
2mM L-glutamine, 100U/ml penicillin/streptomycin, 1x GIBCO MEM Non-essential amino-acids,1mM Sodium pyruvate and 55mM
beta-mercaptoethanol (Thermo Fisher).
HUVEC cells (Thermo Fisher) have been cultured in Medium 200 (Thermo Fisher) supplemented with Low Growth Serum Supple-
ment (Thermo Fisher),
METHOD DETAILS
Cell culture and drug treatments
Thymocytes have been isolated using 70mm Corning Cell Strainers and cultured in RPMI medium. For proliferation experiments,
5x 106 thymocytes have been activated in vitro for up to 4 days in 48well plate with 1mg/ml PHA (Calbiochem) and 10ng/ml mouse
IL2 (R&D System). 10mM EdU 2 hours pulse has been given to the cells to stain the proliferating ones. 10mM nocodazole (Sigma-Al-
drich) o.n. treatment has been performed to synchronize in vitro 3-days activated thymocytes in G2-M phase after pre-treatment with
1mMCFSE (eBioscience) for 15min at 37C. Then, to visualize dividing cells (halving of CFSE fluorescence), cells have been washed
twice and resuspended in RPMI complete medium with 1mg/ml PHA and 20ng/ml mouse IL-2. Thymocyte apoptosis has been
induced in 96well plate stimulating 5x 105 thymocytes with 50mM etoposide (Sigma) or using o.n. plate-coated 96well plate with
10mg/ml anti-TCRb, 10mg/ml anti-CD28 and 50mg/ml anti-CD2 (Biolegend) antibodies as described (Punt et al., 1994).
Mature CD4+ and CD8+ T cells have been isolated from spleen or LNs bymagnetic sorting, using the mouse CD4+ or CD8+ T cell
Isolation Kit (Miltenyi) and then cultured in RPMI medium as described for thymocytes. For in vitro activation, 2x 105 CD4+ or CD8+
T cells have been stimulated with 5mg/ml anti-CD3 (plate-coated) (Biolegend), 1mg/ml anti-CD28 (Biolegend) and 20ng/ml mouse
IL-2 (R&D System) for 2 days. Then the cells have been cultured for additional 3 or 4 days in presence of mIL2 only. For evaluation of
IFNg, TNFa, IL2, Tbet and Eomes expression, 20ng/ml mouse IL12 (R&DSystem) and 10mg/ml anti-mouse-IL4 antibody (Biolegend)
have been added to the cells all the days (th1 or tc1 polarizing conditions). For evaluation of IL4 in CD4+ T, 100ng/ml mouse IL4
(R&D System) and 10mg/ml anti-mouse-IL12 and anti-mouse IFNg antibodies (Biolegend) have been added to the cells all the
days (th2 polarizing conditions). To inhibit mTOR and ERK signaling, activated T cells have been incubated with 10nM RAD-001
(Novartis Oncology) or 33mM FR180204 (R&D System) respectively for 48 hours. Wild-type T cells have been also treated with
1mg/ml ionomycin 1h or with 2mM AICAR (Sigma-Aldrich) for 5h (in presence of aCD3/CD28/IL2). Activated T cells have been
also incubated with 10mM BAPTA-AM (Sigma) and 10mM EDTA (Sigma) or with Compound-C (Sigma) at 2 mM. Calcium uptake
has been analyzed by pre-incubating isolated T cells with 2.5nM Fluo3-AM for 30min at 37C and then stimulating the cells with
rat aCD3 antibody (eBioscience) on ice for 30min. Fluo3-AM baseline fluorescence has been measured by flow cytometry and
then secondary anti-rat antibody have been added immediately to the cells. Fluo3-AM fluorescence have been then acquiredCell Reports 25, 3059–3073.e1–e10, December 11, 2018 e6
for up to 6min. Maximum (at 2min) and residual (at 6min) calcium uptake has been calculated as the ratio of Fluo3-AM fluorescence
between indicated point (maximumor residual) and baseline value. To studymitochondrial accumulation at immunological synapse
(IS), CD4+ and CD8+ T cells have been mixed 1:1 ratio for 2h at 37C with 25mg/ml anti-CD3 antibody (Biolegend) coated latex
sulfate 5mm beads (Molecular Probes) in presence of 1mg/ml anti-CD28 (Biolegend) and 20ng/ml mouse IL-2 and then fixed and
processed for immunostaining. For the analysis of intracellular cytokine production (IFNg, TNFa, IL2), activated T cells have
been restimulated with 5mg/ml anti-CD3 (plate-coated), 1mg/ml anti-CD28 and 20ng/ml mouse IL2 for 6h (2mMmonensin (BD Phar-
Mingen) added for the last 3 hours). T cell cytotoxicity has been evaluated 6 days after initial activation by stimulating the cells for
4 hours with 5mg/ml anti-CD3 (plate-coated) and 1mg/ml anti-CD28 antibodies in 96well plate or at 1:1 ratio with 25mg/ml anti-CD3
antibody- and 100mg/ml anti-CD28 antibody-coated beads (then fixed for immunostaining). For detection of T cell degranulation,
1:200 anti-CD107a (LAMP1, eBioscience) antibody and 2mM monensin have been added for the entire assay. 10mM nocodazole
(Sigma-Aldrich) o.n. treatment has been performed to synchronize in vitro activated T cells in G2-M phase after pre-treatment with
1mMCFSE (eBioscience) for 15min at 37C. Then, to visualize dividing cells (halving of CFSE fluorescence) cells have been washed
twice and resuspended in RPMI complete medium with 20ng/ml mouse IL-2. The Click-iT EdU AlexaFluor-488 Flow Cytometry
Assay Kit has been used to identify EdU+ proliferating cells by flow cytometry, after 10mMEdU pulse of 2 or 24 hours (as described
in detail for each experiment) (Thermo Fisher) and FxCycle Red has been used to quantify DNA content. To investigate lymphope-
nia, mtYFP+ +/+ cre+ control and fl/fl cre+ Drp1 KO CD3+ T cells have been isolated from spleen and naive T cells purified with
magnetic sorting (using CD44 Microbeads from Naive CD4+ T cell Isolation kit, Miltenyi). Then cells have been injected i.v. into
either +/+ cre+ control and fl/fl cre+ Drp1 conditional KO recipient mice. After 10 days, cells have been collected from spleen
and the percentage of exogenous cells expressing the memory marker CD44 analyzed by flow-cytometry.
Flow cytometry
Staining of membrane bound or intracellular antigens has been performed using the following fluorochrome-conjugated monoclonal
antibodies: anti-CD4, anti-CD8a, anti-CD25, anti-CD62L, anti-CD69, anti-TCRgd, anti-CD45, anti-ICAM1, anti-IL7Ra, anti-B220,
anti-F4/80, anti-TNFa, anti-IL2, anti-cd11c, anti-cd11b, anti-IAIE, anti-NK1.1, anti-CD49b (Biolegend), anti-KLRG1, anti-CD38,
anti-S1p-R1, anti-CXCR4, anti-CCR7, anti-CD44, anti-IFNg, anti-Tbet, anti-Eomes, anti-CXCR5, anti-PD1, anti-CX3CR1, anti-
CD107a, anti-granzymeB, anti-Foxp3 (eBioscience) and anti-H2AX-pSer139 (BD Bioscience). For extracellular staining, cells have
been incubated with the indicated antibodies in Dulbecco Phosphate Buffer Saline (DPBS) with 0,5% Bovine Serum Albumin
(BSA, Sigma) at RT for 20min, then washed once before flow-cytometric measurement. For intracellular staining, the cells have
been fixed and permeabilized using the Foxp3 Staining Buffer Set (eBioscience). Thymocytes and mature T cells viability has
been assayed by AnnexinV-FITC Apoptosis Detection kit (eBioscience). For evaluation of mitochondrial membrane potential in thy-
mocytes, 1mM TMRE (Mitochondrial Membrane Potential Assay Kit, Abcam) has been added for 30min and then, after washing, the
cells have been analyzed by flow cytometry. 20mM FCCP (Mitochondrial Membrane Potential Assay Kit, Abcam) has been added
10min before TMRE, as a positive control for membrane potential reduction. Total ATP amount has been measured by using the
ATP assay kit (Abcam). ROS amounts have been quantified using the DCFDA Cellular ROS Detection Assay kit (Abcam). Mitochon-
drial mass has been evaluated by incubating cells with 100nM Mitotracker Green (Thermo Fisher) and then, after washing, the cells
have been analyzed by flow cytometry. Glucose uptake has been evaluated by preincubating T cells for 2 hours in sterile glucose-free
medium (Dulbecco BPS supplemented with 10% FBS, 2mM L-glutamine, 100U/ml penicillin/streptomycin, 1x GIBCO MEM Non-
essential amino-acids, 1mM Sodium pyruvate, 100mg/ml Gentamycin and 55mM beta-mercaptoethanol). Then 2-NBDG has been
added to the cells at the final concentration of 60mM. After 30min, cells have been analyzed by flow cytometry. Data were
acquired on LSR Fortessa (Becton Dickinson) or BD Accuri C6 (Becton Dickson) and analyzed with FlowJo software (version 10.1r5).
Polarization and migration assay
Polarization and transwell migration assays have been performed as previously described (Campello et al., 2006). Briefly, thymocytes
or 6 days in vitro activated T cells have been starved 4 hours in RPMI medium FBS-free (replaced by BSA). For the polarization assay,
1-5x 105 cells have been allowed to adhere to 10mg/ml fibronectin-coated (Sigma Aldrich) microscope slides (Thermo Fisher) for
30min and then stimulated by adding 50nM of CXCL12, CCL19 or CCL21 50nM (R&D System) for 15min. When indicated, cells
have been pre-treated with 50mM mdivi-1 (Sigma Aldrich), 30mM nocodazole or 1 mM oligomycin (Sigma Aldrich) one hour before
chemokine addition and drugs were left during the whole assay duration. When indicated, mature T cells have been stimulated
with 100nM CCL21 in presence of 33mM FR180204 for 20min (DMSO as control).
For transwell assays 5x 105 thymocytes or 1x 105 activated T cells have been plated on 3mm- (thymocytes) or 8mm- (T cells) pore
size transwell filters and allowed to migrate for 1h in presence or not of 50nM CXCL12, 25nM CCL19, 50nM CCL21 and 100nM S1p
(Tocris). For transendothelial migration, transwell 1mg/ml gelatin- (Biorad) and 10mg/ml fibronectin-coated (Sigma-Aldrich) 8mm-pore
filters have been coated 5 days before the assay with 5x 104 HUVEC (Thermo Fisher) grown in Medium 200 plus Low Growth Serum
Supplement (Thermo Fisher), to reach a confluent monolayer.
Live imaging migration has been performed on 6 days in vitro activated T cells. 1x 104 T cells loaded with 1mM CFSE or 5mM
CMTMR (Thermo Fisher) were mixed at 1:1 ratio and added to gelatin- (Bio-Rad) and fibronectin- coated Glass Bottom Culture
Dishes plates (MakTek) in which 5x 104 HUVEC were plated 5 days before the assay, to reach a confluent monolayer. HUVECe7 Cell Reports 25, 3059–3073.e1–e10, December 11, 2018
has been pre-activated o.n. with 10ng/ml TNFa (R&D system) before the assay. Video recording has been performed using a Perkin
Elmer Ultraview VoX every 30sec for up to 1 hour at 37C with 5% CO2 in RPMI complete medium.
Immunofluorescence on cells and frozen sections
For immunofluorescence staining, cells have been fixed in 4% formaldehyde (Carlo Erba Reagents) 15min, permeabilized in Triton-X
0,3% (Sigma) 20min, blocked 1h at RT with 1% BSA (Sigma Aldrich) and immunostained with the following primary anti-mouse an-
tibodies o.n. at 4C: anti-TOM20 (Santa Cruz), anti-b-tubulin, anti-ICAM1 (Biolegend), anti-ATPb (Abcam), anti-pMLC2 (Cell
Signaling), anti-Drp1 (BD PharMingen). All primary antibody incubations have been followed by incubation with appropriated fluoro-
chrome-conjugated secondary antibodies 1h at RT. For g-tubulin staining cells have been fixed with methanol 3min at 20C and
then immediately immunostained with the primary antibody o.n. at 4C. Images were acquired using a Perkin Elmer Ultraview
VoX. The mitochondrial network has been always evaluated upon 0.4mm slices z stack reconstructions. For the identification/quan-
tification of mitochondrial morphology, themean (area/perimeter)/circularity index of themitochondrial network has been calculated,
for each cell, by using the ImageJ Mito-Morphology macro (Dagda et al., 2009); it is indicated in the Figures as ‘‘fusion index.’’
Mice thymus, LNs and salivary glands were fixed o.n. in 4% para-formaldehyde (Sigma Aldrich) followed by 2-days incubation in
30% sucrose (Sigma Aldrich). Then, they have been mixed in 50:50 sucrose:OCT (Sakura) solution 3h at RT and frozen at 80C.
Cryostat sections were obtained by using Leica CM1850UV cryostat and 100mg/ml poly-L-lysine-coated (Sigma Aldrich) Superfrost
slides (Thermo Fisher). Sections were let air-dry on slides, fixed again in 4% para-formaldehyde 10min at RT, permeabilized with
Triton-X 0,3% and blocked 1h with 10% FBS (GIBCO) and incubated with the following anti-mouse primary antibodies o.n. at
4C: anti-keratin-5 (Abcam), anti-CD4, anti-CD8, anti-B220 (Biolegend). All primary antibody incubations were followed by incubation
with appropriate fluorochrome-conjugated secondary antibodies 1h at RT. TUNEL assay was performed on cryostat sections before
immunofluorescence by using the ApopTag Red in situ Apoptosis Detection Kit (Merck Millipore), following manufacturer instruc-
tions. Sections were then directly blocked with 10% Fetal Bovine Serum 1h at RT and incubated with primary antibodies o.n. at 4C.
MCA38-induced subcutaneous tumors
53 105 MCA38 cells were injected subcutaneously into the right flank of two-month old male control and Drp1 conditional KOmice.
Mice were kept for up to 18 days in animal facility, and tumor growth was monitored twice per week and recorded as longest
diameter 3 (shortest diameter)2 (in cubic millimeters). After 18 days, mice were sacrificed and tumors, spleen and inguinal DLNs
were collected. Tumor tissue were mechanically dissociated over 70 mm-cell strainers, and mononuclear cells were enriched from
tumor-derived cell suspensions by 40%/80% Percoll (GE Healthcare) density gradient, by collecting cells at the interface between
40% and 80% Percoll solution. T cells were extracted from LNs and spleen as previously described. After isolation, cells were
restimulated 4h with 50ng/ml PMA (Sigma Aldrich), 1mg/ml ionomycin (Sigma Aldrich) and 2mM monensin (eBioscience), and then
staining for surface and intracellular antigens was performed. Dead cells have been excluded using Fixable Viability Dye eFluor780
(eBioscience) staining. CD8+ T cells recognizing the H-2Kb-restricted immunodominant MCA38 epitope have been identified using
H-2Kb/KSPWFTTL dextramer APC (Immudex). Mixed tumor cell lymphocyte culture (MTLC) have been established to expand CD8+
T cells from spleen of MC38-bearing mice. Briefly, 5 3 106 splenocytes have been cultivated in vitro with 20ng/ml IL2, 20ng/ml
IL15 and 2.5 3 104 UV-irradiated MC38 cells for 10 days in 48well plates (last two days without MC38 cells). Then CD8+ T cells
have been magnetically purified (Miltenyi) and re-stimulated for 6 hours with a-CD3 antibodies (plate coated) or with MC38 cells
(1:10 target:effector ratio), in presence of 1:200 anti-CD107a antibody and 2mMmonensin, in 48well plate to study their cytotoxicity.
MC38 viability has been evaluated by AnnexinV-FITC Apoptosis Detection kit (eBioscience) and CD8+ T cell degranulation by
cytofluorimetric analysis of CD107a staining.
Adoptive Cell Immunotherapy
Splenocytes fromROSA26:mtYFP fl/fl control (+/+ cre+) or Drp1 KO (fl/fl cre+) mice have been isolated and expanded in vitro 14 days
in presence of IL2, IL15 and an irradiated layer of MC38 tumor cells. Medium and MC38 layer have been changed every two days.
Then expanded T cells have been purified using CD3+ Pan T cell Isolation Kit (Miltenyi) and injected i.v. into wild-type mice bearing a
7days-old MC38-derived tumor. Receiving mice have been randomized into two groups with either control cells or Drp1 KO cells
injection. Tumor size has been assessed three times a week and after two weeks mice have been sacrificed and TILs isolated
from tumor mass for cytofluorimetric analysis.
In vivo homing
Control and Drp1 KO mature CD4+ and CD8+ cells from 2-months old mice have been activated in vitro for 6 days as previously
described. Then cells have been labeled with 1mM CFSE (KO) or 5mM Cell Viability dye eFluor670 (eBioscience) (control), mixed at
1:1 ratio, and 4x 106 mixed cells have been injected intravenously (i.v.) through lateral tail veins of wild-type age-matched recipient
tumor-free or tumor-bearing mice (the latter subcutaneously injected with MCA38 cells 13 days before adoptive T cell transfer). After
24h, mice were sacrificed and blood, spleen, LNs and tumor were harvested. After T cell isolation from LN, spleen and tumor, the
number of transferred control and Drp1 KO T cells was quantified by flow cytometry and the KO/control T cells ratio in the blood,
LNs, spleen and tumor of recipient mice was determined, after correcting for the starting injected ratio. Ectopic TILs density has
been evaluated also on cryostat tumor slice by manually counting control (+/+ cre+; Cell Viability Dye eFluor670+) and KO (fl/flCell Reports 25, 3059–3073.e1–e10, December 11, 2018 e8
cre+; CFSE+) T cells after applying fluorescence masking filter by Volocity software to enhance and better detect fluorescent
labeled cells.
Immunohistochemistry
The tumors were fixed in 10% neutral buffered formalin and included in paraffin. 4mm-thick tissue sections obtained from paraffin
embedded tissues were deparaffinized, rehydrated and stained with H&E to define tumor histotypes. Immunohistochemistry was
performed using a polymer detection method. Briefly, the antigen retrieval was performed using Novocastra Epitope Retrieval So-
lution pH 9 in a PT Link Dako pre-treatment module at 98C for 30 minutes. Subsequently, the sections were brought to room tem-
perature and washed in PBS. After neutralization of the endogenous peroxidase with 3%H2O2 and Fc blocking by a specific protein
block (Novocastra UK), the samples were incubated with primary antibodies. For rat anti-mouse monoclonal CD8a (4SM15) or CD4
(4SM95) 1:100 pH9 (eBioscience) antibodies, the staining was revealed using goat anti-rat IgG (H&L) specific secondary antibody
1:500 (Novex by Life Technologies) and AEC (3-Amino-9-ethylcarbazole) substrate-chromogen. Slides were analyzed under a Zeiss
Axioscope A1 andmicrophotographs were collected using a Zeiss Axiocam 503 Color with the Zen 2.0 Software (Zeiss). Quantitative
IHC data for CD8 and CD4 marker was calculated by counting the number of CD8+ or CD4+ cells in five fields at 40X magnification.
Electroporation
6-days in vitro expanded control and Drp1 KO T cells have been electroporated with pEYFP-C1 (empty vector) or pEYFP-C1-
Drp1S616E plasmids following manufacturer instructions (Neon Transfection System, Thermo Fisher). After 24 hours, cells have
been used for transwell assays or have been expanded in IL2 medium for analyzing proliferation. pEYFP-C1-Drp1S616E plasmid
have been generated from pEYFP-C1-Drp1 plasmid using the following primers:
d) Fw primer: 50-ATTCCAATTATGCCAGCCGAGCCACAAAAAGGTC ATGCCGTgaacctgctagatgtgccag-30;
d) Rv primer: 50-ACGGCATGACCTTTTTGTGGCTCGGCTGGCATA ATTGGAATgggttttgatttttcttctg-30
In vivo stimulation with LPS plus MC38 extract
MC38 tumor cell lysate has been obtained by 5 consecutive freeze-thaw (80C/37C) cycles of MC38 cells. Then, lysate has been
centrifuged at 15000g 15min and quantified using Bradford reagent (Bio-Rad). All procedures have been performed under sterile
conditions. Mice have been injected i.p. with 50mg lipopolysaccharide (LPS) (unpulsed) or with 50mg LPS plus 30mg of MC38 lysate
(pulsed). After 4 days, mice have been sacrificed and T cells isolated from spleen for cytofluorimetric analysis.
Seahorse analysis
The metabolic profile has been evaluated in 6-days in vitro activated T cells. Real-time measurements of extracellular acidification
rate (ECAR) and oxygen consumption rate (OCR) were performed using an XFe-96 Extracellular Flux Analyzer (Seahorse Bioscience).
Cells were plated in XFe-96 plates (Seahorse Bioscience) at the concentration of 4 3 105 cells/well, 12 hours before making the
assay, in complete RPMI-1640 medium. ECAR was measured in XF media in basal condition and in response to 10mM glucose,
4mM oligomycin and 100mM of 2-DG (all from Sigma Aldrich). Indices of glycolysis were calculated from ECAR profile: glycolysis
(glyc) (calculated as the difference of ECAR induced by glucose and ECAR induced by 2-DG) and maximal glycolytic capacity
(MGC) (calculated as the difference of ECAR induced by oligomycin and ECAR induced by 2-DG). OCR was measured in XF media
(non-buffered DMEMmedium, containing 10mMglucose, 2mML-glutamine, and 1mMsodium pyruvate), under basal conditions and
in response to 5mM oligomycin, 1.5mM of carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP) and 1mM of rotenone and
antimycin (all from Sigma Aldrich). Indices of mitochondrial respiration were calculated from OCR profile: basal OXPHOS (Basal OX)
(calculated as the difference of basal OCR and OCR induced by rotenone+antimycin) and maximum respiratory capacity (MRC)
(calculated as the difference of OCR induced by FCCP and OCR induced by rotenone+antimycin). For the analysis of FA oxidation
(FAO), we used the XF Palmitate-BSA FAO substrate (Seahorse Bioscience). Briefly FAO was measured in FAO buffer containing
NaCl 111mM, KCl 4.7mM,MgSO4 2.0mM, Na2HPO4 1.2mM, supplemented with 2.5mMglucose, 0.5mMcarnitine and 5mMHEPES
(final concentrations) with pH to 7.4.We added etomoxir (Sigma Aldrich) (40mMfinal) 15min prior to the XF assay being initiated (t = 0).
Indices of FAO were calculated from FAO profile: basal (calculated as the ratio of basal OCR in the presence of palmitate and basal
OCR in the presence of palmitate+etomoxir) and maximal (calculated as the ratio of OCR induced by FCCP in the presence of palmi-
tate and OCR induced by FCCP the presence of palmitate+etomoxir). Experiments with the Seahorse system were done with the
following assay conditions: 3min mixture; 3min wait; and 3min measurement.
RNA-sequencing
T cells have been stimulated with a-CD3 plate-coated and CD28/IL2 for 3 days and then frozen for RNA extraction and analysis. Next
generation RNA-sequencing experiments, comprising samples quality control and Bioinformatics analysis, were performed by
Genomix4life S.R.L. (Baronissi, Salerno, Italy). Indexed libraries were prepared from 1mg/ea purified RNA with TruSeq Stranded
mRNA (Illumina) Library Prep Kit according to the manufacturer’s instructions. Libraries were quantified using the 4200 TapeStation
(Agilent Technologies) and pooled such that each index-tagged sample was present in equimolar amounts, with final concentratione9 Cell Reports 25, 3059–3073.e1–e10, December 11, 2018
of the pooled samples of 2nM. The pooled samples were subject to cluster generation and RNA-sequencing using an Illumina
NextSeq500 (Illumina) in a 1x75 single end (mRNA-sequencing) format.
Data analysis
Bioinformatics analysis was performed by Genomix4Life srl (Baronissi (SA), Italy). The raw sequence files generated (.fastq files) un-
derwent quality control analysis using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and then aligned to the
mouse genome (mm10 assembly) using STAR v.2.5.2 (Dobin et al., 2013), with standard parameters. Raw counts were computed
with HTSeq-count v.0.6.1 (Anders et al., 2015) and differentially expressed mRNAs were identified using DESeq2 v.1.12 (Love
et al., 2014). FPKM counts were computed using Cufflinks (Trapnell et al., 2010). Gene Set Association Analysis (GSAA) (Xiong
et al., 2014) of the expression data was used to assess enrichment of our selected gene lists derived from the following target lists:
d) glycolysis: REACTOME_GLYCOLISYS, integrated with genes from KEGG_GLYCOLYSIS_ GLUCONEOGENESIS and
Pdk1-2-3-4 (Gerriets et al., 2015) and Ldha-b (Rogatzki et al., 2015);
d) for TCA cycle: KEGG_CITRATE_CYCLE_TCA_CYCLE;
d) for OXPHOS: KEGG_OXIDATIVE_PHOSPHORYLATION;
d) for pentose pathway: KEGG_PENTOSE_PHOSPHATE_PATHWAY;
d) for FA synthesis: REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS;
d) for FA catabolism REACTOME_MITOCHONDRIAL_FATTY_ACID_BETA_OXIDATION integrated with genes from KEGG_
FATTY_ACID_METABOLISM;
d) cMyc-dependent metabolic genes, i.e., those metabolic genes which are downregulated in cMyc KO T cells upon activation,
have been obtained from (Wang et al., 2011).
We used the GSAASeqSP tool, a Java based desktop application (software GSAA 2.0), according to the manufacturer’s instruc-
tions (Xiong et al., 2014). We have used the default setting choosing Signal2Noise_log2Ratio for differential expression analysis of
individual genes. For each pathway, the Normalized Association Score (NAS) indicates the relative enrichment (positive value) or
downregulation (negative value) in KO cells compared to controls. The corresponding adjusted p values (pval) and the False
Discovery Rates (FDR) are also reported.
PCR and Western Blotting
DNA from tails and thymus of +/+ cre+ control and fl/fl cre+ Drp1 conditional KOmice has been isolated using alkaline lysis (Tris-HCl
pH8 50mM - EDTA 100mM - NaCl 100mM - SDS 1%) followed by incubation into saturated salt solution and isopropanol precipita-
tion. For PCRmixture preparation G2-Flexi Polymerase has been used (Promega). The following primers have been used for Lck:cre
genotyping: Lck:cre forward (50-cggtcgatgcaacgagtgatgagg-30), Lck:cre reverse (50-ccagagacggaaatccatcgctcg-30). Primers for
Drp1 alleles are described in literature (Ishihara et al., 2009).
For western Blotting, cells have been lysed in RIPA buffer 20min on ice (Tris-HCl 50mM pH8, NaCl 150mM, Nonidet-P40 1%,
Sodium deoxycolate 0.5%, SDS 0.1%) supplemented with Protease Inhibitor Cocktail (Thermo Fisher) and 1mM NaVO4. Samples
were then centrifuged at 4C 20min and denatured 5min at 95C in NuPage LDS Sample Buffer (Invitrogen) (with 5% beta-mercap-
toethanol). Samples were run on 8%, 10% or 13% polyacrylamide gels and transferred on PVDF membranes (Biorad) by using
Mini-Trans Blot Cell (Bio-Rad). Membranes were blocked in 3% w/v milk (Bio-Rad) plus 0.1% Tween20 (Sigma-Aldrich) and
incubated with the appropriate antibodies o.n. at 4C. The following antibodies were used: anti-Drp1 (BD PharMingen), anti-
pS616-Drp1, anti-pmTOR-S2481, anti-mTOR, anti-pAMPKa-T172, anti-AMPKa, anti-cMyc, anti-pS6-S240/244, anti-ERK, anti-
pERK-T202T204 (Cell Signaling), anti-Opa1 (BD PharMingen), anti-MnSOD (Enzo Life Science), anti-actin (Millipore), anti-TOM20,
anti-Mfn1 (Santa Cruz), anti-Fis1, anti-Mff, anti-MiD51 and anti-Mfn2 (Abcam). All primary antibody incubations were followed by in-
cubation with appropriated secondary HRP-conjugated antibodies (GEHealthcare) in 3%milk plus 0.1%Tween20. Detection of pro-
tein signals was performed using Amersham ECL Detection Reagent (GE Healthcare) on Amersham hyperfilms (GE Healthcare).
QUANTIFICATION AND STATISTICAL ANALYSIS
For all experiments shown, n (number of mice used) is indicated in the Fig. legends. Data are expressed as mean ± SEM from at least
three independent experiments unless specified otherwise (Microsoft Office Excel, Prisme and SigmaPlot have been used for
analysis). In dot density plot, mean value is shown in red. Comparison between two groups was done using homoscedastic unpaired
two-tailed Student’s t test, unless data were normalized (control value set as one) in which case heteroscedastic unpaired two-tailed
Student’s t test was used. One-way and two-way ANOVA have been used for multiple comparison (with post hoc Holm-Sidak’s test).
P-values are indicated in the Fig.s as follows: * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
DATA AND SOFTWARE AVAILABILITY
The RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) Database under ID code GEO: GSE112143.Cell Reports 25, 3059–3073.e1–e10, December 11, 2018 e10
